Abstract
Colony-stimulating factors (CSFs) are proteins that play normal roles in human hematopoietic physiology. Many of these factors have been cloned and sequences. This has led to recombinant DNA technology that now allows for production of large quantities of pharmacologically pure compounds. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are two such compounds that have been approved by the US Food and Drug Administration for human use in specific medical circumstances. This article summarizes the experience of one institution in using these two CSFs and adds brief commentary on four other CSFs that are expected to come to general use in the near future--interleukin-1, interleukin-3, interleukin-6, and erythropoietin. Both G-CSF and GM-CSF are effective in protecting patients from the leukotoxic effects of cancer chemotherapy, but GM-CSF appears to have a comparatively narrow "dosing window," wherein the agent is effective and tolerable. Future studies should address combining these agents with platelet protective compounds to improve patient safety.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- DeVita V. T., Jr The influence of information on drug resistance on protocol design. Ann Oncol. 1991 Feb;2(2):93–106. doi: 10.1093/oxfordjournals.annonc.a057892. [DOI] [PubMed] [Google Scholar]
- Donahue R. E., Seehra J., Metzger M., Lefebvre D., Rock B., Carbone S., Nathan D. G., Garnick M., Sehgal P. K., Laston D. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science. 1988 Sep 30;241(4874):1820–1823. doi: 10.1126/science.3051378. [DOI] [PubMed] [Google Scholar]
- Groopman J. E., Molina J. M., Scadden D. T. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med. 1989 Nov 23;321(21):1449–1459. doi: 10.1056/NEJM198911233212106. [DOI] [PubMed] [Google Scholar]
- Holmes F. A., Walters R. S., Theriault R. L., Forman A. D., Newton L. K., Raber M. N., Buzdar A. U., Frye D. K., Hortobagyi G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18;83(24):1797–1805. doi: 10.1093/jnci/83.24.1797-a. [DOI] [PubMed] [Google Scholar]
- Rusthoven J., Levin L., Eisenhauer E., Mazurka J., Carmichael J., O'Connell G., Bryson P., Hirte H., Koski B. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst. 1991 Dec 4;83(23):1748–1753. doi: 10.1093/jnci/83.23.1748. [DOI] [PubMed] [Google Scholar]
- Sarosy G., Kohn E., Stone D. A., Rothenberg M., Jacob J., Adamo D. O., Ognibene F. P., Cunnion R. E., Reed E. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol. 1992 Jul;10(7):1165–1170. doi: 10.1200/JCO.1992.10.7.1165. [DOI] [PubMed] [Google Scholar]
- Shea T. C., Mason J. R., Storniolo A. M., Newton B., Breslin M., Mullen M., Ward D. M., Miller L., Christian M., Taetle R. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol. 1992 Mar;10(3):464–473. doi: 10.1200/JCO.1992.10.3.464. [DOI] [PubMed] [Google Scholar]
- The lymphomas: current concepts in pathogenesis and management. Washington, D.C., September 21-23, 1989. Proceedings. J Natl Cancer Inst Monogr. 1990;(10):1–82. [PubMed] [Google Scholar]